Jan. 9, 2014 11:00 UTC

MicroPort Scientific Corporation and Sorin Group Sign Joint Venture Agreement for Cardiac Rhythm Management Business in China

MicroPort and Sorin to enter the fast growing Chinese Cardiac Rhythm Management market

SHANGHAI & MILAN--(BUSINESS WIRE)-- MicroPort Scientific Corporation (HK: 00853) and Sorin Group (MIL:SRN) (Reuters Code: SORN.MI), announced today that they have entered into a definitive agreement to form a joint venture to market and develop cardiac rhythm management (CRM) devices (implantable pacemakers, defibrillators, cardiac resynchronization devices and related devices) in China. MicroPort will hold a 51 percent stake in the joint venture entity, while Sorin will hold the remaining 49 percent interest. In accordance with the agreement, MicroPort and Sorin shall make initial capital contributions of, respectively, RMB62,220,000 (USD10.2 million) and of RMB59,780,000 (USD9.8 million) in cash in the joint-venture company.

The new venture, which will be named MicroPort Sorin CRM (Shanghai) Co. Ltd., will be located in Shanghai and is scheduled to start operations in the first half of 2014. Under the agreement, the two companies will collaborate, through the joint venture, on the import, sale and service of Sorin’s CRM devices in Greater China and, in parallel, in accelerating the development of locally manufactured CRM products for the Chinese market. Significant engineering and development resources from both parties will transition to the joint venture immediately.

This new venture brings together two respected industry leaders, leveraging complementary strengths: MicroPort’s unparalleled Chinese market coverage and strong national reputation and Sorin’s 40 years’ experience in the development and manufacture of high quality and innovative CRM devices. MicroPort and Sorin believe that the joint venture will be well positioned to quickly penetrate the growing CRM market in China. According to industry research, the Chinese CRM market, still underpenetrated, is estimated to be approximately USD500 million, growing approximately 10% per year in the next 5 years.

“This agreement represents a key milestone in MicroPort’s strategy, enabling us to enter in the rapidly growing Chinese CRM market and expanding our high-end medical device product portfolio. We recognize Sorin as an innovative player in the CRM field and we are looking forward to supporting the commercialization of Sorin’s devices and ultimately realizing our goal to develop locally manufactured devices which are specifically designed for China and fit the needs of the growing demand in our country”, commented Dr. Zhaohua Chang, Chairman and Chief Executive Officer of MicroPort Scientific Corporation.

“This is an important milestone in our strategy to build a local presence in China. Access to CRM therapies in China is expected to expand rapidly and the market should grow at double digit rates in the foreseeable future. Expanding our footprint in China in CRM is key to our long-term growth strategy,” said André-Michel Ballester, Chief Executive Officer of Sorin Group. “MicroPort, whose strong reputation, broad distribution network and talented management team is recognized by its customers, is the ideal CRM partner for Sorin in China.”

The transaction is subject to customary closing conditions, including receipt of regulatory clearances.

About MicroPort

MicroPort Scientific Corporation. is a leading medical device company publicly listed on the main board of Hong Kong (HK853). The Group focuses on innovating, manufacturing, and marketing high-quality and yet still affordable high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 30 seconds in over 2,000 major hospitals throughout China and over 20 other countries, MicroPort maintains operations in a wide range of business segments including Cardiovascular Devices, Orthopedic Devices, Electrophysiological Devices, Endovascular Devices, Neurovascular Devices, Surgical Management, Diabetes Care and Endocrinal Management, and others. MicroPort is dedicated to becoming a leading global enterprise capable of providing the best and most affordable medical products and technologies to patients throughout the world.

For more information, please refer to www.microport.com.

About Sorin Group

Sorin Group (Reuters Code: SORN.MI), is a global medical device company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With 3,750 employees worldwide, the Company focuses on two major therapeutic areas: Cardiac Surgery (cardiopulmonary products for open heart surgery and heart valve repair or replacement products) and Cardiac Rhythm Management (pacemakers, defibrillators, cardiac resynchronization devices). Every year, over one million patients are treated with Sorin Group devices in more than 80 countries.

For more information, please refer to www.sorin.com.

Contacts

Gabriele Mazzoletti, Tel: +39 02 69969785
Mobile: +39 348 9792201
Director, Corporate Communications
Sorin Group
e-mail: gabriele.mazzoletti@sorin.com
or
Francesca Rambaudi, Tel: +39 02 69969716
Director, Investor Relations
Sorin Group
e-mail: investor.relations@sorin.com
or
Jonathan Chen, Tel: (86)(21) 38954600
Vice President, International Business & Investor Relations
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Email: jonathanchen@microport.com
or
Xun You, Tel: (86)(21) 38954600-5168
Board Secretary
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Email: ir@microport.com


Source: Sorin Group